How to Get Zetia (Ezetimibe) in Georgia: Prescriptions, Telehealth, and Pharmacy Access

What Is Ezetimibe and Why Doctors Prescribe It

Ezetimibe blocks cholesterol absorption at the brush border of the small intestine by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) transporter. As a standalone agent, it lowers LDL-C by 18 to 25 percent. Added to statin therapy, that reduction compounds meaningfully.

The IMPROVE-IT trial (N=18,144, published in NEJM 2015) remains the defining outcomes study for ezetimibe. Patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg alone. The combination arm reached a median LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the monotherapy arm (p<0.001), and the primary composite cardiovascular endpoint was reduced by 6.4 percent over 7 years (HR 0.936 to 95% CI 0.887 to 0.988, p=0.016) [1]. This was the first randomized trial to confirm that adding a non-statin agent to statin therapy reduces hard cardiovascular events.

The FDA approved ezetimibe (Zetia) for adjunct treatment of primary hyperlipidemia in 2002 [2]. The American College of Cardiology and American Heart Association 2018 Cholesterol Guideline classes ezetimibe as a Class IIa recommendation for patients with clinical ASCVD whose LDL-C remains above 70 mg/dL despite maximally tolerated statin therapy [3].

Ezetimibe is also studied as monotherapy for patients with statin intolerance. A 2022 Cochrane review of 19 trials (N=4,798) found ezetimibe monotherapy reduced LDL-C by 20.4 mg/dL compared with placebo (95% CI 18.0 to 22.8 mg/dL) [4]. Tolerability was comparable to placebo across all trials reviewed.

Who Can Prescribe Zetia in Georgia

Any licensed Georgia prescriber, physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) can write a prescription for ezetimibe 10 mg. Georgia law does not restrict the drug class to physician-only prescribing, and NPs and PAs operating under Georgia Code Title 43 may prescribe Schedule V and non-scheduled medications including lipid-lowering agents without physician co-signature in most practice settings [5].

Telehealth prescribers must hold an active Georgia medical license or qualify under Georgia's interstate telehealth statute. The Georgia Composite Medical Board permits audio-video telehealth encounters for establishing a new patient-provider relationship, meaning a first-time ezetimibe prescription may be issued after a synchronous video visit without a prior in-person examination [6].

Prescriptions are valid for 12 months from the date issued. Ezetimibe carries no DEA schedule, so there is no limit on refills per prescription under Georgia law.

Labs Required Before Starting Zetia in Georgia

A fasting lipid panel is the standard pre-prescription lab for ezetimibe. The panel measures total cholesterol, LDL-C, HDL-C, and triglycerides. Fasting for 9 to 12 hours before the draw improves triglyceride accuracy; LDL-C calculated via the Friedewald equation requires a triglyceride value below 400 mg/dL [7].

Most telehealth providers in Georgia require a lipid panel result dated within the past 12 months. If the patient has none, a standing lab order can be placed at any LabCorp, Quest, or hospital outpatient lab in Georgia before or simultaneous with the prescriber visit. Some providers accept results from a patient's primary care physician faxed directly to the telehealth platform.

Liver function tests (AST, ALT) are not required by the FDA label for ezetimibe alone [2]. However, the 2018 ACC/AHA guideline recommends baseline ALT when ezetimibe is added to high-intensity statin therapy, because the combination modestly increases the rate of hepatic enzyme elevation compared with statin monotherapy [3]. The IMPROVE-IT trial reported no significant difference in hepatitis or myopathy rates between the combination arm and the statin-only arm [1].

A complete metabolic panel (CMP) and creatinine are sometimes ordered when prescribing clinicians want to baseline renal function, particularly in patients over 65 or those with diabetes. The ezetimibe dose does not require renal adjustment for CrCl above 30 mL/min [2].

How to Get a Zetia Prescription Through Georgia Telehealth

Georgia telehealth prescribing for ezetimibe follows a predictable four-step sequence.

Step 1: Select a licensed Georgia telehealth provider. Platforms operating in Georgia with lipid management services include large national telehealth services (Teladoc, MDLive) and specialty cardiovascular or metabolic telehealth practices. Confirm the provider holds a current Georgia license before booking.

Step 2: Complete the intake and upload labs. Most platforms accept a PDF of your most recent lipid panel. If you do not have labs, request a same-day order; LabCorp and Quest both offer walk-in draws at dozens of Georgia locations [8].

Step 3: Attend the synchronous video visit. Georgia's telehealth statute requires a real-time audio-video encounter to establish a new patient relationship before prescribing. Visits typically run 15 to 20 minutes. The prescriber reviews your lipid values, cardiovascular risk factors, current medications, and any contraindications.

Step 4: Receive and fill the prescription. After the visit, the prescriber sends an e-prescription to your preferred Georgia pharmacy via the state's e-prescribing network. Most pharmacies dispense generic ezetimibe same-day or next-day. Mail-order pharmacies typically deliver within two to three business days.

The entire sequence from booking to prescription-in-hand can be completed in under 48 hours for most Georgia patients with a recent lipid panel on file.

Georgia Pharmacies That Dispense Ezetimibe

Generic ezetimibe 10 mg is stocked at virtually every retail pharmacy chain operating in Georgia, including CVS, Walgreens, Walmart Pharmacy, Publix Pharmacy, Kroger Pharmacy, and Costco Pharmacy. Publix offers a 30-day supply of select generic cholesterol medications at no charge under its free medication program, though ezetimibe availability at no cost varies by location [9].

GoodRx and manufacturer discount cards frequently bring the cash price of generic ezetimibe 10 mg (30 tablets) below $20 at Georgia pharmacies. The brand-name Zetia carries a retail price of $300 or more per month without insurance; nearly all clinical guidelines and payers recommend the generic, which is bioequivalent per FDA standards [2].

503A Compounding Pharmacies in Georgia

Georgia 503A pharmacies are state-licensed sterile and non-sterile compounders regulated by the Georgia Board of Pharmacy. These pharmacies may compound ezetimibe into custom dose forms (suspensions for dysphagia patients, combination capsules) when a prescriber documents a clinical need that the commercially available tablet cannot meet. The FDA's 503A framework requires a valid patient-specific prescription and prohibits compounding copies of commercially available products without a specific documented need [10].

Patients seeking compounded ezetimibe in Georgia should confirm the pharmacy holds current Georgia Board of Pharmacy licensure and, for sterile preparations, USP 797 compliance documentation [11].

Georgia Insurance Coverage and Prior Authorization

Commercial insurance: Most major Georgia commercial plans (Anthem BCBS Georgia, UnitedHealthcare, Aetna, Cigna) cover generic ezetimibe on Tier 2 or Tier 3 of their formularies. Tier 2 copays typically run $10 to $50 per 30-day fill. Brand Zetia is often excluded or placed on non-preferred Tier 4, requiring prior authorization (PA) or step therapy [12].

Step therapy requirements: Many Georgia commercial plans require documented failure of or intolerance to at least one high-intensity statin before approving ezetimibe. Documentation needed typically includes: (a) the statin tried, dose, and duration; (b) the reason for discontinuation or insufficient response (LDL-C lab value); and (c) current LDL-C on existing therapy.

Georgia Medicaid (Pathways HE, CMO plans): Ezetimibe is covered under Georgia Medicaid for patients with type 2 diabetes as a cardiovascular risk-reduction agent. For the general hyperlipidemia indication without diabetes, Georgia Medicaid does not currently cover ezetimibe. Patients in this situation should ask their prescriber about statin-plus-ezetimibe combinations or apply for the Merck patient assistance program (Zetia Savings Card) [13].

Medicare Part D: Ezetimibe appears on the formularies of most Georgia Medicare Part D plans, typically Tier 2 or Tier 3. The Extra Help low-income subsidy program reduces the copay to $0 to $4 for qualifying beneficiaries [14].

The following decision framework summarizes the prior authorization evidence package most Georgia commercial insurers accept:

| Evidence Item | Acceptable Documentation | |---|---| | Statin trial | Prescription record or pharmacy fill history, minimum 90 days | | Reason for add-on | LDL-C lab value above goal while on statin | | LDL-C goal threshold | Typically <70 mg/dL for ASCVD; <100 mg/dL for primary prevention | | Statin intolerance | Two documented statin trials with myalgia or CK elevation noted in chart | | Supporting guideline | ACC/AHA 2018 Cholesterol Guideline Class IIa recommendation |

Transferring a Zetia Prescription to Georgia

Patients relocating to Georgia with an active ezetimibe prescription from another state can transfer the prescription to any Georgia retail pharmacy. Non-controlled prescriptions may be transferred between pharmacies in different states under federal law. The receiving Georgia pharmacist contacts the originating pharmacy to verify the prescription and remaining refills.

If the originating prescription is expired or the patient needs a new one, a telehealth provider licensed in Georgia can issue a fresh prescription after reviewing the patient's records. A letter of continuing care or chart notes from the prior prescriber, combined with a current lipid panel, is typically sufficient to document clinical continuity [6].

Patients who used a mail-order pharmacy in their prior state can switch to a Georgia mail-order or local pharmacy. Most 90-day supply plans reset to a 30-day local fill when a transfer is initiated.

Clinical Evidence Supporting Ezetimibe Beyond IMPROVE-IT

The SHARP trial (N=9,270, published in The Lancet 2011) tested simvastatin 20 mg plus ezetimibe 10 mg versus placebo in patients with chronic kidney disease. The combination reduced major atherosclerotic events by 17 percent (RR 0.83 to 95% CI 0.74 to 0.94, p=0.0021) [15]. This was the first large outcomes trial showing lipid lowering benefit specifically in the CKD population, and the ACC/AHA guideline now cites SHARP as supporting evidence for ezetimibe use in non-dialysis CKD patients [3].

A 2021 meta-analysis in the Journal of the American College of Cardiology pooled 14 statin-plus-ezetimibe randomized trials (N=41,114) and found the combination reduced major adverse cardiovascular events by 10 percent compared with statin monotherapy (RR 0.90 to 95% CI 0.84 to 0.96) [16]. LDL-C reductions were proportionally consistent with the 1-mmol/L-per-event-reduction relationship established by the Cholesterol Treatment Trialists' Collaboration [17].

For patients with heterozygous familial hypercholesterolemia (HeFH), the 2023 European Atherosclerosis Society consensus statement recommends ezetimibe as second-line therapy after maximally tolerated statin, before escalation to PCSK9 inhibitors, based on the additive LDL-C lowering of 15 to 20 percent seen in HeFH-specific studies [18].

Ezetimibe's tolerability profile is one reason prescribers favor it. The SHARP trial reported no excess of myopathy, rhabdomyolysis, or hepatic adverse events in the ezetimibe-combination arm compared with placebo [15]. The FDA label notes that ezetimibe-associated myopathy has been reported rarely and almost exclusively in the context of co-administered fibrates, not statins [2].

Dosing, Drug Interactions, and Contraindications

The approved dose of ezetimibe is 10 mg once daily, taken with or without food, at any time of day [2]. No dose titration exists. The drug is not renally cleared at clinically significant levels, making it safe for most patients with CKD stages 1 through 4 [2].

Interactions to review at the Georgia prescriber visit:

Cyclosporine increases ezetimibe plasma levels 3.4-fold; co-administration requires a risk-benefit discussion and closer LFT monitoring [2]. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption by approximately 55 percent; ezetimibe should be taken at least 2 hours before or 4 hours after the sequestrant [2]. Fibrates (gemfibrozil, fenofibrate) increase ezetimibe glucuronide levels; co-administration with gemfibrozil is listed as a caution rather than a contraindication in the label [2].

Contraindications: Ezetimibe is contraindicated during pregnancy (FDA Category X when combined with statins, though ezetimibe alone lacks controlled human data) and active hepatic disease with unexplained persistent transaminase elevations [2]. Patients planning pregnancy in Georgia should discuss this with their prescriber before initiating treatment.

What Georgia Patients Should Bring to Their First Zetia Appointment

A focused checklist shortens the prescriber visit and reduces the chance of prior authorization delays.

Bring or upload: your most recent fasting lipid panel (within 12 months), a current medication list with doses, any prior statin prescriptions and the reason they were stopped or continue, your insurance card and pharmacy preference, and any cardiac history documents (stress test, catheterization report, or cardiology notes). If your LDL-C goal is being assessed for ASCVD risk, a recent blood pressure reading and your HbA1c (if diabetic) are also relevant [3].

Georgia patients over 40 without established ASCVD may benefit from a 10-year ASCVD risk score calculated using the Pooled Cohort Equations, which the ACC/AHA guideline uses to determine statin intensity and ezetimibe candidacy [3]. Most telehealth platforms calculate this score automatically from intake data.

The ACC 2022 expert consensus on non-statin therapies states that "for patients with LDL-C >= 70 mg/dL on maximally tolerated statin therapy who have established ASCVD, ezetimibe is the preferred next step before initiating PCSK9 inhibitor therapy given its favorable cost and evidence base" [19].

Starting ezetimibe 10 mg once daily and confirming a follow-up lipid panel at 6 to 12 weeks is the standard of care [3].